Supporting Treatment decision making to Optimise the Prevention of STROKE in Atrial Fibrillation: The STOP STROKE in AF study. Protocol for a cluster randomised controlled trial

Implementation Science

Nicholas Zwar²  Dominic Y Leung¹  John M Worthington³  Melina Gattellari² 

[1] Department of Cardiology, Liverpool Health Service, South Western Sydney Local Health Network, Liverpool, Australia;School of Public Health and Community Medicine, The University of New South Wales, Sydney, Australia;Department of Neurology, Liverpool Health Service, South Western Sydney Local Health Network, Liverpool, Australia

关键词: Decisional support;    Anticoagulation;    General practice;    Atrial fibrillation;   

Others  :  814805
DOI  :  10.1186/1748-5908-7-63

 received in 2012-05-09, accepted in 2012-07-06,  发布年份 2012

【 摘 要 】

Background

Suboptimal uptake of anticoagulation for stroke prevention in atrial fibrillation has persisted for over 20 years, despite high-level evidence demonstrating its effectiveness in reducing the risk of fatal and disabling stroke.

Methods

The STOP STROKE in AF study is a national, cluster randomised controlled trial designed to improve the uptake of anticoagulation in primary care. General practitioners from around Australia enrolling in this ‘distance education’ program are mailed written educational materials, followed by an academic detailing session delivered via telephone by a medical peer, during which participants discuss patient de-identified cases. General practitioners are then randomised to receive written specialist feedback about the patient de-identified cases either before or after completing a three-month posttest audit. Specialist feedback is designed to provide participants with support and confidence to prescribe anticoagulation. The primary outcome is the proportion of patients with atrial fibrillation receiving oral anticoagulation at the time of the posttest audit.

Discussion

The STOP STROKE in AF study aims to evaluate a feasible intervention via distance education to prevent avoidable stroke due to atrial fibrillation. It provides a systematic test of augmenting academic detailing with expert feedback about patient management.

Trial registration

Australian Clinical Trials Registry Registration Number: ACTRN12611000076976.

【 授权许可】

   
2012 Gattellari et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Lake FR, Cullen KJ, de Klerk NH, McCall MG, Rosman DL: Atrial fibrillation and mortality in an elderly population. ANZ Med 1989, 19:321-326.
• [2]Wolf PA, Abbot RD, Kannel WB: Atrial fibrillation as an independent risk factor for stroke: the Framingham study. Stroke 1991, 22:983-988.
• [3]Gattellari M, Goumas C, Aitken R, Worthington JM: Outcomes for patients with ischaemic stroke and atrial fibrillation: The PRISM study (A Program of Research Informing Stroke Management). Cerebrovasc Dis 2011, 32:370-382.
• [4]Hart RG, Pearce LA, Aguilar MI: Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007, 146:857-867.
• [5]Hart RG, Pearce LA, Aguilar MI: Adjusted-dose warfarin versus aspirin for preventing stroke in patients with atrial fibrillation (author’ reply). Ann Intern Med 2007, 147:591.
• [6]Mant J, Hobbs R, Fletcher K, Roalfe A, Fitzmaurice D, Lip GYH: Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): A randomised controlled trial. Lancet 2007, 370:493-503.
• [7]Olgilvie IM, Welner SA, Cowell W, Lip GY: Characterization of the proportion of untreated and antiplatelet therapy treated patients with atrial fibrillation. Am J Cardiol 2011, 108:151-61.
• [8]Olgilvie IM, Newton N, Welner SA, Cowell W, Lip GYH: Underuse of oral anticoagulants in atrial fibrillation. A systematic review. Am J Med 2010, 123:638-645.
• [9]Bajorek BV, Krass I, Ogle SJ, Duguid MJ, Shenfield GM: Optimizing the use of antithrombotic therapy for atrial fibrillation in older people: a pharmacist-led multidisciplinary intervention. J Am Geriatric Soc 2005, 53:1912-20.
• [10]Gladstone DJ, Bui E, Fang J, Laupacis A, Lindsay MP, Tu JV, Silver FL, Kapral MK: Potentially preventable strokes in high-risk patients with atrial fibrillation who are not adequately anticoagulated. Stroke 2009, 40:235-240.
• [11]Ahmad O, Ahmad KE, Dear KBG, Harvey I, Hughes A, Lueck CJ: Atrial fibrillation and anticoagulation in a stroke unit population. Internal Medicine Journal 2009, 39:752-56.
• [12]Pugh D, Pugh J, Mead GE: Attitudes of physicians regarding anticoagulation for atrial fibrillation: a systematic review. Age and Ageing 2011, 40:675-83.
• [13]Gattellari M, Worthington J, Zwar N, Middleton S: Barriers to the use of anticoagulation for non-valvular atrial fibrillation (NVAF): a representative survey of Australian family physicians. Stroke 2008, 39:227-230.
• [14]Gattellari M, Worthington JM, Zwar NA, Middleton S: The management of non-valvular atrial fibrillation (NVAF) in Australian general practice: bridging the evidence-practice gap. A national, representative postal survey. BMC Fam Pract 2008, 9:62. BioMed Central Full Text
• [15]Shen A, Cordato D, Ng J, Hung WT, Kokkinos J, Karr M, Yin Chan DK: Anticoagulant usage for primary stroke prevention: a general practitioner survey in local areas of metropolitan Sydney. J Clin Neurosci 2008, 15:166-71.
• [16]Peterson GM, Boom K, Jackson SL, Vial JH: Doctors’ beliefs on the use of antithrombotic therapy in atrial fibrillation: identifying barriers to stroke prevention. Internal Medicine Journal 2002, 32:15-23.
• [17]Arendts G, Krishnaraj M, Paull G, Rees D: Management of atrial fibrillation in the acute setting: findings from an Australasian survey. Heart, Lung & Circulation 2010, 19:423-7.
• [18]Zimetbaum PJ, Thosani A, Yu HT, Xiong Y, Lin J, Kothawala P, Emons M: Are atrial fibrillation patients receiving warfarin in accordance with stroke risk? Am J Med 2010, 123:446-53.
• [19]Mazzaglia G, Filippi A, Alacqua M, Cowell W, Shakespeare A, Mantovani LG, Bianchi C, Cricelli C: A national survey of the management of atrial fibrillation with antithrombotic drugs in Italian primary care. Thromb Haemost 2010, 103:968-75.
• [20]Poli D, Antonucci E, Testa S, Tosetto A, Ageno W, Palareti G, Italian Federation of Anticoagulation Clinics: Bleeding risk in very old patients on vitamin K antagonist treatment: results of a prospective collaborative study on elderly patients followed by Italian Centres for Anticoagulation. Circulation 2011, 124:769-71.
• [21]Singer DE, Chang Y, Fang MC, Borowsky LH, Pomernacki NK, Udaltsova N, Go AS: The net clinical benefit of warfarin: anticoagulation in atrial fibrillation. Ann Intern Med 2009, 151:297-305.
• [22]Garwood CL, Corbett TL: Use of anticoagulation in elderly patients with atrial fibrillation who are at risk for falls. Annals of Phamacotherapy 2008, 42:523-32.
• [23]Man-Son-Hing M, Nichol G, Lau A, Laupacis A: Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls. Arch Intern Med 1999, 159:677-85.
• [24]Gage BF, Birman-Deych E, Kerzner R, Radford MJ, Nilasena DS, Rich MW: Incidence of intracranial hemorrhage in patients with atrial fibrillation who are prone to fall. Am J Med 2005, 118:612-7.
• [25]McAlister FA, Man-Son-Hing M, Straus SE, Ghali WA, Anderson D, Majumdar PG, Cox JL, Fradette M, for the Decision Aid in Atrial Fibrillation (DAAFI) Investigators: Impact of a patient decision aid on care among patients with nonvalvular atrial fibrillation: a cluster randomized trial. CMAJ 2005, 173:496-501.
• [26]Jackson SL, Peterson GM, Vial JH: A community-based educational intervention to improve antithrombotic drug use in atrial fibrillation. Ann Pharmacother 2004, 38:1794-1799.
• [27]Ornstein S, et al.: A multimethod quality improvement intervention to improve preventive cardiovascular care: a cluster randomized trial. Ann Intern Med 2004, 141:523-32.
• [28]Wright J, Bibby J, Eastham J, Harrison S, McGeorge M, Patterson C, Price N, Russell D, Russel I, Small N, Walsh M, Young J: Multifaceted implementation of stroke prevention guidelines in primary care: cluster-randomised evaluation of clinical and cost effectiveness. Qual Saf Health Care 2007, 16:51-59.
• [29]Allen KR, Hazelett S, Jarjoura D, Wickstrom GC, Hua K, Weinhardt J, Wright K: Effectiveness of a postdischarge care management model for stroke and transient ischemic attack: a randomized trial. Journal of Stroke and Cerebrovascular Disease 2001, 11:88-98.
• [30]Banet GA, Felchlia MA: The potential utility of a shared medical record in a ‘first-time’ stroke population. J Vasc Nurs 1997, 15:29-35.
• [31]Ellis G, Rodger J, McAlpine C, Langhorne P: The impact of stroke nurse specialist input on risk factor modification: a randomised controlled trial. Age Ageing. 2005, 34:389-392.
• [32]Joubert J, Reid C, Barton D, Cumming T, McLean A, Joubert L, Barlow J, Ames D, Davis S: Integrated care improves risk-factor modification after stroke: initial results of the Integrated Care for the Reduction of Secondary Stroke model. J Neurol Neurosurg Psychiatry 2009, 80:279-284.
• [33]Wolfe CDA, Redfern J, Rudd AG, Grieve AP, Heuschmann PU, McKevitt C: Cluster randomized controlled trial of a patient and general practitioner intervention to improve the management of multiple risk factors after stroke. Stop Stroke. Stroke. 2010, 41:2470-2476.
• [34]Choudhry NK, Soumerai SB, Normand SLT, Ross Degnan D, Laupacis A, Anderson GM: Warfarin prescribing in atrial fibrillation: the impact of physician, patient and hospital characteristics. Am J Med 2006, 119(Choudhry NK, Soumerai SB, Normand SLT):607-615.
• [35]Gattellari M, Leung DY, Ukoumunne OC, Zwar N, Grimshaw J, Worthington JM: Study protocol: The DESPATCH study: Delivering stroke prevention for patients with atrial fibrillation- a cluster cluster randomised controlled trial. Implement Sci 2011, 6:48. BioMed Central Full Text
• [36]. . http://www.ampcodirect.com.au/DynamicPages.asp?cid=11&navid=2 webcite last accessed January2, 2012
• [37]Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ: Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001, 285:2864-70.
• [38]Hankey GJ, on behalf of the National Blood Pressure Advisory Committee of the National Heart Foundation: Non-valvular atrial fibrillation and stroke prevention Position Statement. MJA 2001, 174:234-239.
• [39]Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Kay GN, Le Huezey JY, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann LS, Smith SC, Priori SG, Estes NA, Ezekowitz MD, Jackman WM, January CT, Lowe JE, Page RL, Slotwiner DJ, Stevenson WG, Tracy CM, Jacobs AK, Anderson JL, Albert N, Buller CE, Creager MA, Ettinger SM, Guyton RA, Halperin JL, Hochman JS, Kushner FG, Ohman EM, Stevenson WG, Tarkington LG, Yancy CW, American College of Cardiology Foundation/American Heart Association Task Force: 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2011, 123:e269-367.
• [40]Albers GW, Amarenco P, Easton JD, Sacco RL, Teal P, American College of Chest Physicians: Antithrombotic and thrombolytic therapy for ischemic stroke: American College of Chest Physicians Evidence-based Clinical Practice Guidelines (8th Edition). Chest 2008, 13:630S-669S.
• [41]Baker RI, Coughlin PB, Gallus AS, Harper PL, Salem HH, Wood EM: Position statement. Wafarin reversal: consensus guidelines, on behalf of the Australasian society of thrombosis and haemostasis. MJA 2004, 181:492-497.
• [42]Effect of clopidogrel added to aspirin in patients with atrial fibrillation N Eng J Med 2009, 360:2066-2078.
• [43]Connolly S, Pogue J, Hart R, Pfeffer M, Hohnloser S, Chrolavicius S, Pfeffer M, Hohnloser S, Yusuf S, ACTIVE Writing Group of the ACTIVE Investigators: Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE W): a randomized controlled trial. Lancet 2006, 367:1903-1912.
• [44]Gallus AS, Baker RI, Chong BH, Ockelford PA, Street AM, On behalf of the Australasian Society of Thrombosis and Haemostatis: Position statement. Consensus guidelines for warfarin therapy. Recommendations from the Australasian Society of Thrombosis and Haemostatis. Medical Journal of Australia 2000, 172:600-605.
• [45]Lip GYH, Nieuwlaat R, Pisters R, Lane DA, Crijns HJGM: Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor based approach: the Euro Heart Survey on atrial fibrillation. Chest 2010, 137:263-272.
• [46]Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darious J, Deiner HC, Joyner CD, Wallentin L: RE-LY Steering Committee and Investigators. Dabigatra versus warfain in patients with atrial fibrillation. N Engl J Med 2009, 361:1139-51.
• [47]Connolly SJ, Ezekowitz MD, Yusyf S, Reilly PA, Wallentin L, for the Randomised Evaluation of Long-term Anticoagulation Therapy Investigators: Newly identified events in the RE-LY trial. N Engl J Med 2010, 363:1875-1876.
• [48]Dabigatran (Pradaxa). NPS Radar Review. . http://www.nps.org.au/news_and_media/media_releases/repository/Dabigatran_Pradaxa_NPS_RADAR_Review webcite. Last accessed January 2, 2012
• [49]Therapeutic Goods Administration. . http://www.tga.gov.au/safety/alerts-medicine-dabigatran-111005.html webcite Last accessed Janaury 2, 2012
• [50]Dolan JG: Method for evaluating health care providers’ decision making: the Provider Decision Process Assessment Instrument. Medical Decision Making 1991, 19:38-41.
• [51]Lip GYH, Frison L, Halperin JL, Lane DA: Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. J Am Coll Cardiol 2011, 57:173-80.
• [52]McAlister FA, Fradette M, Graham M, Majumdar SR, Ghali WA, Williams R, Tsuyuki RT, McMeekin J, Grimshaw J, Knudtson ML: A randomized trial to assess the impact of opinion leader endorsed evidence summaries on the use of secondary prevention strategies in patients with coronary artery disease: The ESP-CAD trial protocol (NCT00175240). Implement Sci 2006, 1:11. BioMed Central Full Text
• [53]Paiken JS, Mehta SR, Eikelboom JW: Role of triple antithrombotic therapy in patients with atrial fibrillation and coronary artery stents. Medical Journal of Australia 2010, 192:487-488.
• [54]Hansen ML, Sorensen R, Clausen MT, Fog-Petersen ML, Raunso J, Gadsboll N, Gislason GH, Folke F, Andersen SS, Schramm TK, Abildstrom SZ, Poulsen HE, Kober L, Torp-Pedersen C: Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med 2010, 170:1433-41.
• [55]Rubboli A, Halperin JL, Airaksinen KE, Buerke M, Eeckhout E, Freedman SB, Gershlick AH, Schlitt A, Tse HF, Verheugt FW, Lip GY: Antithrombotic therapy in patients treated with oral anticoagulation undergoing coronary artery stenting. An expert consensus document with focus on atrial fibrillation. Annals of Medicine 2008, 40:428-36.
• [56]Dupont WD, Plummer WD: Power and sample size calculations: a review and computer program. Control Clin Trials 1990, 11:116-28.
• [57]Murray DM: Design & analysis of group randomized trials. Oxford University Press, NY; 1998.
• [58]Patel MR, Maheffrey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM: Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011, 365:883-91.
• [59]Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L, ARISTOTLE Committees and Investigators: Apixaban versus warfarin in patients with atrial fibrillation. New England Journal of Medicine 2011, 365:981-92.
• [60]Zoller ML: Dabigatran’s first A-Fib year starts warfarin’s decline. eCardiology News. . http://www.ecardiologynews.com/news/arrhythmias-electrophysiology/single-article/dabigatran-s-first-a-fib-year-starts-warfarin-s-decline/446ecf58b7.html webcite , November 13, 2011. Last accessed January 2, 2012
• [61]Federal Drugs Administration. . http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm282820.htm webcite Last accessed January 2, 2012
• [62]Choudhry NK, Anderson GM, Laupacis A, Ross-Degnan D, Normant SLT, Soumerai SB: Impact of adverse events on prescribing warfarin in patients with atrial fibrillation: matched pair analysis. BMJ 2006, 332:141-145.
• [63]Bajorek BV, Masood N, Krass I: Optimising the utilisation of antithromnotic therapy for stroke prevention in AF. , Hamburg, Germany; May 24-27, 2011. http://www.esc-archive.eu/hamburg11/Ongoing%20Trials%20ESC%20Hamburg%202011.pdf webcite (Last accessed April 15 2012)
• [64]Bajorek BV, Masood N, Krass I: Development of a computerised antithrombotic risk assessment tool (CARAT) to optimise therapy in older persons with atrial fibrillation. Australasian Journal on Ageing 2012, 31:102-09.